Beck Mack & Oliver Has Decreased Grifols S A Sp Adr Rep B Nvt (GRFS) Position; 9 Analysts Bullish MacroGenics, Inc. (MGNX)

May 18, 2018 - By Dolores Ford

Grifols, S.A. (NASDAQ:GRFS) Logo

Beck Mack & Oliver Llc decreased Grifols S A Sp Adr Rep B Nvt (GRFS) stake by 2.32% reported in 2017Q4 SEC filing. Beck Mack & Oliver Llc sold 36,766 shares as Grifols S A Sp Adr Rep B Nvt (GRFS)’s stock declined 9.37%. The Beck Mack & Oliver Llc holds 1.55M shares with $35.47M value, down from 1.58 million last quarter. Grifols S A Sp Adr Rep B Nvt now has $18.22 billion valuation. It closed at $22.47 lastly. It is down 11.04% since May 18, 2017 and is uptrending. It has underperformed by 0.51% the S&P500.

Among 11 analysts covering MacroGenics (NASDAQ:MGNX), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. MacroGenics had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Citigroup given on Thursday, August 4. The company was maintained on Thursday, August 6 by Stifel Nicolaus. The rating was maintained by Leerink Swann on Wednesday, October 25 with “Buy”. On Wednesday, March 14 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. SunTrust maintained the stock with “Buy” rating in Friday, September 1 report. Stifel Nicolaus maintained it with “Buy” rating and $34.0 target in Monday, September 11 report. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Neutral” rating given on Thursday, September 17 by Citigroup. As per Friday, January 19, the company rating was maintained by BTIG Research. The firm earned “Buy” rating on Tuesday, January 23 by SunTrust. The stock has “Buy” rating by SunTrust on Tuesday, December 20. See MacroGenics, Inc. (NASDAQ:MGNX) latest ratings:

06/04/2018 Broker: Leerink Swann Rating: Buy New Target: $35.0000 Initiate
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 New Target: $26 Maintain
05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38 Initiates Coverage On
23/01/2018 Broker: SunTrust Rating: Buy New Target: $31.0 Maintain
19/01/2018 Broker: BTIG Research Rating: Buy New Target: $28.0 Maintain
11/12/2017 Broker: Raymond James Rating: Buy

Another recent and important Grifols, S.A. (NASDAQ:GRFS) news was published by Prnewswire.com which published an article titled: “Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents” on May 14, 2018.

Among 5 analysts covering Grifols SA (NASDAQ:GRFS), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Grifols SA had 8 analyst reports since August 17, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 17 by Nomura. As per Tuesday, February 9, the company rating was upgraded by Berenberg. The stock has “Overweight” rating by JP Morgan on Tuesday, January 3. The firm has “Underweight” rating given on Monday, January 4 by Morgan Stanley. The firm has “Hold” rating by Berenberg given on Friday, November 20. HSBC downgraded the stock to “Hold” rating in Wednesday, December 2 report.

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.47, from 1.58 in 2017Q3. It is negative, as 14 investors sold MacroGenics, Inc. shares while 31 reduced holdings. 15 funds opened positions while 35 raised stakes. 28.26 million shares or 1.97% more from 27.72 million shares in 2017Q3 were reported. Bank Of Ny Mellon Corporation invested 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Ubs Asset Mgmt Americas has invested 0.01% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Artal Group holds 0.03% or 100,000 shares. Gam Hldg Ag invested in 22,600 shares. Dekabank Deutsche Girozentrale accumulated 228,500 shares. Goldman Sachs holds 0% or 65,108 shares. Voya Mgmt Ltd Liability Company holds 0.02% or 577,181 shares. Ameritas Invest Prns has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). State Street Corporation owns 1.05 million shares for 0% of their portfolio. Teacher Retirement Systems Of Texas invested in 11,823 shares or 0% of the stock. Metropolitan Life Insurance, New York-based fund reported 11,734 shares. Pennsylvania-based Susquehanna Limited Liability Partnership has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Moreover, Art Ltd Company has 0.03% invested in MacroGenics, Inc. (NASDAQ:MGNX). The Georgia-based Invesco has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Us Savings Bank De invested in 572 shares or 0% of the stock.

The stock increased 0.75% or $0.16 during the last trading session, reaching $21.5. About 14,603 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 31.18% since May 18, 2017 and is uptrending. It has outperformed by 19.63% the S&P500.

Since January 16, 2018, it had 0 insider buys, and 7 sales for $1.10 million activity. $100,000 worth of MacroGenics, Inc. (NASDAQ:MGNX) was sold by Wigginton Jon Marc on Tuesday, January 16. $67,500 worth of MacroGenics, Inc. (NASDAQ:MGNX) shares were sold by Risser Eric Blasius. Cilinski Lynn had sold 23,967 shares worth $599,436 on Wednesday, February 28. $155,000 worth of stock was sold by Karrels James on Monday, March 5.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $907.35 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

More notable recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: Globenewswire.com which released: “MacroGenics to Present at Deutsche Bank Health Care Conference” on May 07, 2018, also Seekingalpha.com with their article: “MacroGenics’ (MGNX) CEO Scott Koenig on Q1 2018 Results – Earnings Call Transcript” published on May 08, 2018, Globenewswire.com published: “MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call” on April 30, 2018. More interesting news about MacroGenics, Inc. (NASDAQ:MGNX) were released by: Bizjournals.com and their article: “Md. biotech to be acquired by New Jersey pharmaceutical goliath” published on May 08, 2018 as well as Benzinga.com‘s news article titled: “36 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: May 08, 2018.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: